Founded with a mission to revolutionize the treatment of bacterial infections, Uniphage leverages the combined power of bacteriophages and artificial intelligence. The company's vision is to provide sustainable, microbe-based alternatives to traditional antibiotics, starting with their primary focus on combating citrus greening disease, a major agricultural issue costing the U.S. over $2 billion annually. Uniphage has developed the first commercially effective models for computationally predicting safe bacterial viruses against specific bacterial infections, aiming to offer innovative solutions in the biotech sector.

Notable figures affiliated with Uniphage include leading experts in biotechnology and artificial intelligence. The company has attracted significant interest from investors focused on sustainable agriculture and biotech innovation. Key achievements include the successful creation of predictive models for bacteriophage efficacy and the identification of multiple bacterial targets. Uniphage's impact is seen in its potential to transform agricultural disease management and reduce reliance on chemical treatments, positioning it as a pioneer in the biotech industry.